Myeloid suppressors decrease melanoma survival by abating tumor-fighting t cells

Clinical Cancer Research

Volumn 20, Issue 6, 2014, Pages 1401-1403

  Kiessling, Rolf ^a   Mao, Yumeng ^a   De Coana, Yago Pico ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

MELAN A; NY ESO 1 ANTIGEN;

ADVANCED CANCER; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CAUSAL ATTRIBUTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; HUMAN; LYMPHOCYTE FUNCTION; MELANOMA; MYELOID DERIVED SUPPRESSOR CELL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; SURVIVAL PREDICTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; BONE MARROW CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES; T LYMPHOCYTE;

HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; MELANOMA; MYELOID CELLS; T-LYMPHOCYTES;

EID: 84896532267     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-3388     Document Type: Article

References (12)

1. Weide B, Martens A, Zelba H, Stutz C, Derhovanessian E, Di Giacomo AM, et al. Myeloid-derived suppressor cells predict survival of patients with advanced melanoma:Comparison with regulatory T Cells andNYESO-1-or Melan-A-Specific T Cells. Clin Cancer Res 2014;20:1601-9.
2. Sullivan RJ, Lorusso PM, Flaherty KT. The intersection of immunedirected and molecularly targeted therapy in advanced melanoma: wherewehave been, are, andwill be. ClinCancer Res 2013;19:5283-91.
3. Weide B, Zelba H, Derhovanessian E, Pflugfelder A, Eigentler TK, Di Giacomo AM, et al. Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. J Clin Oncol 2012;30:1835-41.
4. Poschke I, Kiessling R. On the armament and appearances of human myeloid-derived suppressor cells. Clin Immunol 2012;144:250-68.
5. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012;12: 253-68.
6. Poschke I, Mougiakakos D, Hansson J, Masucci GV, Kiessling R. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res 2010;70:4335-45.
7. Mougiakakos D, Johansson CC, Kiessling R. Naturally occurring regulatory T cells show reduced sensitivity toward oxidative stressinduced cell death. Blood. 2009;113:3542-5.
8. Whiteside TL. What are regulatory T cells (Treg) regulating in cancer and why? Semin Cancer Biol 2012;22:327-34.
9. Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E, et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A 2008;105:20410-5.
10. Poschke I, Mao Y, Adamson L, Salazar-Onfray F, Masucci G, Kiessling R. Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines. Cancer Immunol Immunother 2012;61:827-38.
11. Schilling B, Sucker A, Griewank K, Zhao F, Weide B, Gorgens A, et al. Vemurafenib reverses immunosuppression by myeloid derived suppressor cells. Int J Cancer 2013;133:1653-63.
12. de Coana YP, Poschke I, Gentilcore G, Yumeng M, Nyström M, Hansson Jet al. Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production. Cancer Immunol Res 2013;1:158-62.